ArticleHereditas2025
The diagnostic and prognostic value of LncRNA FAM3D-AS1 expression in nasopharyngeal carcinoma and its effect on tumor progression and cisplatin resistance.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe location of nasopharyngeal carcinoma (NPC) is relatively hidden. Most patients are diagnosed at the middle or late stage of the disease, having missed the best time for treatment.
aimTo explore the clinical value of lncRNA FAM3D-AS1 and its effect on tumor progression and cisplatin resistance in nasopharyngeal cancer. MATERIALS AND
methodsIn this study, a total of 118 NPC patients and 50 healthy volunteers participated. RT-qPCR was analyzed to detect the lncRNA FAM3D-AS1 expression in NPC patients and cells. Receiver Operating Characteristic (ROC curves), Kaplan-Meier (K-M) survival curves and Cox regression analysis were performed to analyze the clinical value value of lncRNA FAM3D-AS1. Cell functional assays were employed to investigate the impact of lncRNA FAM3D-AS1 on biological malignant behavior of NPC and cisplatin resistance.
resultsIn NPC patients' serum and cell lines, the expression of lncRNA FAM3D-AS1 was upregulated. ROC curves with Area Under the Curve (AUC) = 0.920, 95%CI = 0.874-0.965 could be used to distinguish the healthy group from the NPC group. K-M survival curves revealed that NPC patients with high expression of lncRNA FAM3D-AS1 had poor prognosis. Cox regression analysis suggested that lncRNA FAM3D-AS1 was an independent prognostic marker for NPC. Knockdown of lncRNA FAM3D-AS1 expression prohibited NPC cell proliferation, migration, invasion, and cisplatin resistance, but promoted apoptosis.
conclusionLncRNA FAM3D-AS1 can be used as a biomarker to diagnose and prognosticate NPC. LncRNA FAM3D-AS1 affects tumor progression and cisplatin resistance in NPC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.